The DOI matches its Crossref record; 467 of the 467 references it cites were found in a registry or an index.
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Open accessAbstract
RNA-based therapies, including RNA molecules as drugs and RNA-targeted small molecules, offer unique opportunities to expand the range of therapeutic targets. Various forms of RNAs may be used to selectively act on proteins, transcripts, and genes that cannot be targeted by conventional small molecules or proteins. Although development of RNA drugs faces unparalleled challenges, many strategies have been developed to improve RNA metabolic stability and intracellular delivery. A number of RNA drugs have been approved for medical use, including aptamers (e.g., pegaptanib) that mechanistically act on protein target and small interfering RNAs (e.g., patisiran and givosiran) and antisense oligonucleotides (e.g., inotersen and golodirsen) that directly interfere with RNA targets. Furthermore, guide RNAs are essential components of novel gene editing modalities, and mRNA therapeutics are under development for protein replacement therapy or vaccination, including those against unprecedented severe acute respiratory syndrome coronavirus pandemic. Moreover, functional RNAs or RNA motifs are highly structured to form binding pockets or clefts that are accessible by small molecules. Many natural, semisynthetic, or synthetic antibiotics (e.g., aminoglycosides, tetracyclines, macrolides, oxazolidinones, and phenicols) can directly bind to ribosomal RNAs to achieve the inhibition of bacterial infections. Therefore, there is growing interest in developing RNA-targeted small-molecule drugs amenable to oral administration, and some (e.g., risdiplam and branaplam) have entered clinical trials. Here, we review the pharmacology of novel RNA drugs and RNA-targeted small-molecule medications, with a focus on recent progresses and strategies. Challenges in the development of novel druggable RNA entities and identification of viable RNA targets and selective small-molecule binders are discussed. SIGNIFICANCE STATEMENT: With the understanding of RNA functions and critical roles in diseases, as well as the development of RNA-related technologies, there is growing interest in developing novel RNA-based therapeutics. This comprehensive review presents pharmacology of both RNA drugs and RNA-targeted small-molecule medications, focusing on novel mechanisms of action, the most recent progress, and existing challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 467
The Molecular Interactions That Stabilize RNA Tertiary Structure: RNA Motifs, Patterns, and Networks
Butcher, S. E., & Pyle, A. M. (2011) · Accounts of Chemical Research · doi:10.1021/ar200098t · Cited by 362
An mRNA structure in bacteria that controls gene expression by binding lysine
Sudarsan, N., Wickiser, J. K., Nakamura, S., Ebert, M. S., & Breaker, R. R. (2003) · Genes & Development · doi:10.1101/gad.1140003 · Cited by 357
Su, Z., Zhang, Y., Gendron, T. F., Bauer, P. O., Chew, J., Yang, W.-Y., Fostvedt, E., Jansen-West, K., Belzil, V. V., Desaro, P., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.041 · Cited by 356
The Dynamic Landscapes of RNA Architecture
Cruz, J. A., & Westhof, E. (2009) · Cell · doi:10.1016/j.cell.2009.02.003 · Cited by 347
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 336
Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
Sequence-based design of bioactive small molecules that target precursor microRNAs
Velagapudi, S. P., Gallo, S. M., & Disney, M. D. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1452 · Cited by 327
Rand, T. A., Ginalski, K., Grishin, N. V., & Wang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405913101 · Cited by 324
The A-Z of bacterial translation inhibitors
Wilson, D. N. (2009) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409230903307311 · Cited by 322
Discovery and Development of Therapeutic Aptamers
Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105547 · Cited by 320
Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., & Fucini, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804276105 · Cited by 318
Heo, Y.-A. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 317
The Emerging Role of RNA as a Therapeutic Target for Small Molecules
Connelly, C. M., Moon, M. H., & Schneekloth, J. S. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.05.021 · Cited by 316
Revisiting the structures of several antibiotics bound to the bacterial ribosome
Bulkley, D., Innis, C. A., Blaha, G., & Steitz, T. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008685107 · Cited by 308
A Genomewide Search for Ribozymes Reveals an HDV-Like Sequence in the Human CPEB3 Gene
Salehi-Ashtiani, K., Lupták, A., Litovchick, A., & Szostak, J. W. (2006) · Science · doi:10.1126/science.1129308 · Cited by 304
Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit
Ippolito, J. A., Kanyo, Z. F., Wang, D., Franceschi, F. J., Moore, P. B., Steitz, T. A., & Duffy, E. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800379d · Cited by 303
Ribonuclease P: an enzyme with an essential RNA component.
Stark, B. C., Kole, R., Bowman, E. J., & Altman, S. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.3717 · Cited by 301
Stein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble
Stelzer, A. C., Frank, A. T., Kratz, J. D., Swanson, M. D., Gonzalez-Hernandez, M. J., Lee, J., Andricioaei, I., Markovitz, D. M., & Al-Hashimi, H. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.596 · Cited by 291
Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch
Serganov, A., Huang, L., & Patel, D. J. (2009) · Nature · doi:10.1038/nature07642 · Cited by 289
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
Genomewide view of gene silencing by small interfering RNAs
Chi, J.-T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., & Brown, P. O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1037853100 · Cited by 285
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Recent Advances in Developing Small Molecules Targeting RNA
Guan, L., & Disney, M. D. (2012) · ACS Chemical Biology · doi:10.1021/cb200447r · Cited by 280
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278
Efficient nonmeiotic allele introgression in livestock using custom endonucleases
Tan, W., Carlson, D. F., Lancto, C. A., Garbe, J. R., Webster, D. A., Hackett, P. B., & Fahrenkrug, S. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310478110 · Cited by 278
Nair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278
Circular RNAs: A Novel Class of Functional RNA Molecules with a Therapeutic Perspective
Santer, L., Bär, C., & Thum, T. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.001 · Cited by 275
Do natural antisense transcripts make sense in eukaryotes?
Vanhée-Brossollet, C., & Vaquero, C. (1998) · Gene · doi:10.1016/s0378-1119(98)00093-6 · Cited by 271
Thiamine Pyrophosphate Riboswitches Are Targets for the Antimicrobial Compound Pyrithiamine
Sudarsan, N., Cohen-Chalamish, S., Nakamura, S., Emilsson, G. M., & Breaker, R. R. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.007 · Cited by 267
Inhibition of gene expression in plant cells by expression of antisense RNA
Ecker, J. R., & Davis, R. W. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5372 · Cited by 265
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Wang, J., Exline, C. M., DeClercq, J. J., Llewellyn, G. N., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Surosky, R. T., Gregory, P. D., Holmes, M. C., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3408 · Cited by 261
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Pervasive Regulatory Functions of mRNA Structure Revealed by High-Resolution SHAPE Probing
Mustoe, A. M., Busan, S., Rice, G. M., Hajdin, C. E., Peterson, B. K., Ruda, V. M., Kubica, N., Nutiu, R., Baryza, J. L., & Weeks, K. M. (2018) · Cell · doi:10.1016/j.cell.2018.02.034 · Cited by 258
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics
Vater, A., & Klussmann, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.004 · Cited by 250
A stress-responsive RNA switch regulates VEGFA expression
Ray, P. S., Jia, J., Yao, P., Majumder, M., Hatzoglou, M., & Fox, P. L. (2009) · Nature · doi:10.1038/nature07598 · Cited by 249
Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs
Disney, M. D., Winkelsas, A. M., Velagapudi, S. P., Southern, M., Fallahi, M., & Childs-Disney, J. L. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00001 · Cited by 248
Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
Recombinant RNA technology: the tRNA scaffold
Ponchon, L., & Dardel, F. (2007) · Nature Methods · doi:10.1038/nmeth1058 · Cited by 236
Lee, E. R., Blount, K. F., & Breaker, R. R. (2009) · RNA Biology · doi:10.4161/rna.6.2.7727 · Cited by 235
Eteplirsen: First Global Approval
Syed, Y. Y. (2016) · Drugs · doi:10.1007/s40265-016-0657-1 · Cited by 234
CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice
Zhang, Y., Long, C., Li, H., McAnally, J. R., Baskin, K. K., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2017) · Science Advances · doi:10.1126/sciadv.1602814 · Cited by 231
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230
Antibacterial lysine analogs that target lysine riboswitches
Blount, K. F., Wang, J. X., Lim, J., Sudarsan, N., & Breaker, R. R. (2007) · Nature Chemical Biology · doi:10.1038/nchembio842 · Cited by 230
Papachristofilou, A., Hipp, M. M., Klinkhardt, U., Früh, M., Sebastian, M., Weiss, C., Pless, M., Cathomas, R., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 227
Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Muller, M. R., Brugger, W., Horger, M. S., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.289 · Cited by 226
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
Sivaramakrishnan, M., McCarthy, K. D., Campagne, S., Huber, S., Meier, S., Augustin, A., Heckel, T., Meistermann, H., Hug, M. N., Birrer, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01559-4 · Cited by 226
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression
Roy, B., Friesen, W. J., Tomizawa, Y., Leszyk, J. D., Zhuo, J., Johnson, B., Dakka, J., Trotta, C. R., Xue, X., Mutyam, V., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605336113 · Cited by 221
Design of a small molecule against an oncogenic noncoding RNA
Velagapudi, S. P., Cameron, M. D., Haga, C. L., Rosenberg, L. H., Lafitte, M., Duckett, D. R., Phinney, D. G., & Disney, M. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523975113 · Cited by 218
G‐quadruplex‐binding small molecules ameliorate C9orf72 FTD / ALS pathology in vitro and in vivo
Simone, R., Balendra, R., Moens, T. G., Preza, E., Wilson, K. M., Heslegrave, A., Woodling, N. S., Niccoli, T., Gilbert‐Jaramillo, J., Abdelkarim, S., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201707850 · Cited by 214
Zhang, X., Goel, V., & Robbie, G. J. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1553 · Cited by 213
Marciniak, R. A., Garcia-Blanco, M. A., & Sharp, P. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3624 · Cited by 210
Precise small-molecule recognition of a toxic CUG RNA repeat expansion
Rzuczek, S. G., Colgan, L. A., Nakai, Y., Cameron, M. D., Furling, D., Yasuda, R., & Disney, M. D. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2251 · Cited by 209
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Ui-Tei, K., Naito, Y., Nishi, K., Juni, A., & Saigo, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn902 · Cited by 205
Roadmap and strategy for overcoming infusion reactions to nanomedicines
Szebeni, J., Simberg, D., González-Fernández, Á., Barenholz, Y., & Dobrovolskaia, M. A. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0273-1 · Cited by 205
Wilgenhof, S., Van Nuffel, A. M. T., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Van Riet, I., Bonehill, A., Thielemans, K., & Neyns, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt245 · Cited by 203
Infusion Reactions: Diagnosis, Assessment, and Management
Vogel, W. H. (2010) · Clinical Journal of Oncology Nursing · doi:10.1188/10.cjon.e10-e21 · Cited by 201
Structure and function of HCV IRES domains
Lukavsky, P. J. (2009) · Virus Research · doi:10.1016/j.virusres.2008.06.004 · Cited by 201
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems
Rezaee, M., Oskuee, R. K., Nassirli, H., & Malaekeh-Nikouei, B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.023 · Cited by 200 · cited 1×
“, 2006), lipidation of the polyethylenimine-RNApolyplex offers lipopolyplex (LPP), which may retain the benefits of both materials while reducing the toxicity of polyplex (Rezaee et al., 2016).”
BackgroundStrategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Aartsma-Rus, A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0665 · Cited by 196
Dangouloff, T., & Servais, L. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s172291 · Cited by 196
Liposome–polyethylenimine complexes for enhanced DNA and siRNA delivery
Schäfer, J., Höbel, S., Bakowsky, U., & Aigner, A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.043 · Cited by 195
Polyfunctional DNA intercalating agents
Wakelin, L. P. G. (1986) · Medicinal Research Reviews · doi:10.1002/med.2610060303 · Cited by 194
Tapping the RNA world for therapeutics
Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 194
Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
Xu, C., Lu, Z., Luo, Y., Liu, Y., Cao, Z., Shen, S., Li, H., Liu, J., Chen, K., Chen, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06522-5 · Cited by 193
Precise and efficient siRNA design: a key point in competent gene silencing
Fakhr, E., Zare, F., & Teimoori-Toolabi, L. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.4 · Cited by 191
Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 190
Inotersen: First Global Approval
Keam, S. J. (2018) · Drugs · doi:10.1007/s40265-018-0968-5 · Cited by 188
Circular RNAs as Therapeutic Agents and Targets
Holdt, L. M., Kohlmaier, A., & Teupser, D. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01262 · Cited by 187
Synthetic CRISPR RNA-Cas9–guided genome editing in human cells
Rahdar, M., McMahon, M. A., Prakash, T. P., Swayze, E. E., Bennett, C. F., & Cleveland, D. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520883112 · Cited by 186
Synthesis of RNA by In Vitro Transcription
Beckert, B., & Masquida, B. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-59745-248-9_3 · Cited by 181
A Three-Stemmed mRNA Pseudoknot in the SARS Coronavirus Frameshift Signal
Plant, E. P., Pérez-Alvarado, G. C., Jacobs, J. L., Mukhopadhyay, B., Hennig, M., & Dinman, J. D. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030172 · Cited by 181
Weissman, D., Ni, H., Scales, D., Dude, A., Capodici, J., McGibney, K., Abdool, A., Isaacs, S. N., Cannon, G., & Karikó, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4710 · Cited by 178
ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy
Ottesen, E. W. (2017) · Translational Neuroscience · doi:10.1515/tnsci-2017-0001 · Cited by 173
Gurumurthy, C. B., Sato, M., Nakamura, A., Inui, M., Kawano, N., Islam, M. A., Ogiwara, S., Takabayashi, S., Matsuyama, M., Nakagawa, S., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0187-x · Cited by 173
Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3502 · Cited by 172 · cited 1×
“Moreover, a single-dose treatment with inclisiran was shown to cause a durable reduction in LDL cholesterol levels among the subjects over 1 year (Ray et al., 2019), and inclisiran showed similar efficacy and safety profiles among individuals with normal and impaired renal functions (Wright et al.,…”
BackgroundPoirier, A., Weetall, M., Heinig, K., Bucheli, F., Schoenlein, K., Alsenz, J., Bassett, S., Ullah, M., Senn, C., Ratni, H., et al. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.447 · Cited by 172
Crooke, S. T., & Geary, R. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04469.x · Cited by 171
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants
Berisio, R., Harms, J., Schluenzen, F., Zarivach, R., Hansen, H. A. S., Fucini, P., & Yonath, A. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.14.4276-4279.2003 · Cited by 165
Dulla, K., Aguila, M., Lane, A., Jovanovic, K., Parfitt, D. A., Schulkens, I., Chan, H. L., Schmidt, I., Beumer, W., Vorthoren, L., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.07.010 · Cited by 165
Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 165
Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit
Costales, M. G., Haga, C. L., Velagapudi, S. P., Childs-Disney, J. L., Phinney, D. G., & Disney, M. D. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11273 · Cited by 164
How We Think about Targeting RNA with Small Molecules
Costales, M. G., Childs-Disney, J. L., Haniff, H. S., & Disney, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01927 · Cited by 164
RNA therapy: Are we using the right molecules?
Yu, A.-M., Jian, C., Yu, A. H., & Tu, M.-J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 163
Self-citationHaas, M., Vlcek, V., Balabanov, P., Salmonson, T., Bakchine, S., Markey, G., Weise, M., Schlosser-Weber, G., Brohmann, H., Yerro, C. P., et al. (2015) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.11.011 · Cited by 160
Pavco, P. A., Bouhana, K., Gallegos, A. M., Agrawal, A., Blanchard, K. S., Grimm, S., Jensen, K. L., Andrews, L. E., Wincott, F. E., PITOT, P. A., et al. (2000) · PubMed · Cited by 160
A structural basis for streptomycin-induced misreading of the genetic code
DeMirci, H., Murphy, F. V., Murphy, E. L., Gregory, S. T., Dahĺberg, A. E., & Jogl, G. (2013) · Nature Communications · doi:10.1038/ncomms2346 · Cited by 159
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Small molecules targeting viral RNA
Hermann, T. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1373 · Cited by 154
Targeting RNA : A Transformative Therapeutic Strategy
Yin, W., & Rogge, M. C. (2019) · Clinical and Translational Science · doi:10.1111/cts.12624 · Cited by 152
Park, S., Kim, Y., & Park, H. (2011) · Journal of the American Chemical Society · doi:10.1021/ja1098325 · Cited by 150
Engineering and In Vivo Applications of Riboswitches
Hallberg, Z. F., Su, Y., Kitto, R. Z., & Hammond, M. C. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014628 · Cited by 149
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Roccaro, A. M., Sacco, A., Purschke, W. G., Moschetta, M., Buchner, K., Maasch, C., Zboralski, D., Zöllner, S. K., Vonhoff, S., Mishima, Y., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.042 · Cited by 148
Mei, H., Mack, D. P., Galan, A. A., Halim, N. S., Heldsinger, A. A., Loo, J. A., Moreland, D. W., Sannes, K. A., Sharmeen, L., Truong, H. N., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(97)00064-3 · Cited by 148
Mechanism of Action of Streptogramins and Macrolides
Vannuffel, P., & COCITO, C. G. (1996) · Drugs · doi:10.2165/00003495-199600511-00006 · Cited by 147
FDA approves patisiran to treat hereditary transthyretin amyloidosis
Wood, H. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0065-0 · Cited by 145 · cited 7×
“The first siRNA drug, patisiran (Table 2), was approved by the FDA in 2018 for the treatment of the polyneuropathy of hATTR amyloidosis in adults (Wood, 2018; Yu et al., 2019) over 20 years after the discovery of siRNA-controlled gene silencing.”
BackgroundInfluentialParkesh, R., Childs‐Disney, J. L., Nakamori, M., Kumar, A., Wang, E. T., Wang, T., Hoskins, J. W., Tran, T. A., Housman, D. E., Thornton, C. A., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210088v · Cited by 144
Sztuba-Solińska, J., Shenoy, S. R., Gareiss, P. C., Krumpe, L. R. H., Grice, S. F. J. L., O’Keefe, B. R., & Schneekloth, J. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502754f · Cited by 144
Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
Georgiadis, C., Preece, R., Nickolay, L. E., Etuk, A., Petrova, A., Ładoń, D., Danyi, A., Humphryes-Kirilov, N., Ajetunmobi, A., Kim, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.025 · Cited by 141
Fomivirsen approved for CMV retinitis.
Roehr, B. (1998) · PubMed · Cited by 140
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W. B., Barnhart, K. F., Wu, S. Y., Rodriguez‐Aguayo, C., Zhang, X., Coleman, R. L., Lopez‐Berestein, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0541 · Cited by 137
Morgan, B. S., Forte, J. E., Culver, R. N., Zhang, Y., & Hargrove, A. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707641 · Cited by 137
Structural origins of aminoglycoside specificity for prokaryotic ribosomes
Lynch, S. R., & Puglisi, J. D. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4420 · Cited by 134
Cheung, A. K., Hurley, B., Kerrigan, R., Shu, L., Chin, D. N., Shen, Y., O’Brien, G., Sung, M. J., Hou, Y., Axford, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01291 · Cited by 134
Costales, M. G., Suresh, B. M., Vishnu, K., & Disney, M. D. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.04.008 · Cited by 133
Chromatographic methods for the determination of therapeutic oligonucleotides
McGinnis, A. C., Chen, B., & Bartlett, M. G. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.09.007 · Cited by 131
Miniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E. S., Martier, R., Koornneef, A., Southwell, A. L., Hayden, M. R., van Deventer, S. J. H., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.7 · Cited by 131
Karikó, K., & Weissman, D. (2007) · PubMed · Cited by 130
Zhang, X., Goel, V., Attarwala, H. Z., Sweetser, M. T., Clausen, V. A., & Robbie, G. J. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1480 · Cited by 130
Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model
Angelbello, A. J., Rzuczek, S. G., McKee, K., Chen, J. L., Olafson, H. R., Cameron, M. D., Moss, W. N., Wang, E. T., & Disney, M. D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901484116 · Cited by 129
Targeting RNA in mammalian systems with small molecules
Donlic, A., & Hargrove, A. E. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1477 · Cited by 127
Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity
Gehrig, S. M., Eberle, M.-E., Botschen, F., Rimbach, K., Eberle, F., Eigenbrod, T., Kaiser, S., Holmes, W. M., Erdmann, V. A., Sprinzl, M., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111044 · Cited by 126
Zhang, P., Park, H.-J., Zhang, J., Junn, E., Andrews, R. J., Velagapudi, S. P., Abegg, D., Vishnu, K., Costales, M. G., Childs‐Disney, J. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905057117 · Cited by 126
Nguyen, L., Luu, L. M., Peng, S. I., Serrano, J. F., Chan, H. Y. E., & Zimmerman, S. C. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09266 · Cited by 125
The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention
Stevens, M., Clercq, E. D., & Balzarini, J. M. (2006) · Medicinal Research Reviews · doi:10.1002/med.20081 · Cited by 123
Dibrov, S. M., Ding, K., Brunn, N. D., Parker, M. A., Bergdahl, B. M., Wyles, D. L., & Hermann, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118699109 · Cited by 122
Cromer, M. K., Vaidyanathan, S., Ryan, D. E., Curry, B., Lucas, A. B., Camarena, J., Kaushik, M. P., Hay, S., Martin, R. M., Steinfeld, I., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.002 · Cited by 122
Allard, S. D., Keersmaecker, B. D., de Goede, A. L., Verschuren, E. J., Koetsveld, J., Reedijk, M. L., Wylock, C., Bel, A. V. D., Vandeloo, J., Pistoor, F. H. M., et al. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.10.010 · Cited by 121
Ratni, H., Karp, G. M., Weetall, M. L., Naryshkin, N. A., Paushkin, S. V., Chen, K. S., McCarthy, K. D., Qi, H., Turpoff, A., Woll, M. G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00459 · Cited by 119
Gulck, E. R. V., Vlieghe, E., Vekemans, M., Tendeloo, V. F. V., de Velde, A. V., Smits, E., Anguille, S., Cools, N., Goossens, H., Mertens, L., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834f33e8 · Cited by 116
THE VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (V.I.S.I.O.N.) CLINICAL TRIAL GROUP (2005) · Retina · doi:10.1097/00006982-200510000-00001 · Cited by 116
High-performance virtual screening by targeting a high-resolution RNA dynamic ensemble
Ganser, L. R., Lee, J. H., Rangadurai, A., Merriman, D. K., Kelly, M. L., Kansal, A. D., Sathyamoorthy, B., & Al‐Hashimi, H. M. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0062-4 · Cited by 116
Wilber, A. C., Frandsen, J. L., Geurts, J. L., Largaespada, D. A., Hackett, P. B., & McIvor, R. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.014 · Cited by 115
mRNA: Fulfilling the Promise of Gene Therapy
Weissman, D., & Karikó, K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.138 · Cited by 114
Ponchon, L., Beauvais, G., Nonin‐Lecomte, S., & Dardel, F. (2009) · Nature Protocols · doi:10.1038/nprot.2009.67 · Cited by 114
RNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113
Deak, D., Outterson, K., Powers, J. H., & Kesselheim, A. S. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0291 · Cited by 113
Sturm, S., Guenther, A., Jaber, B., Jordan, P., Kotbi, N. A., Parkar, N., Cleary, Y., Frances, N., Bergauer, T., Heinig, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13786 · Cited by 113
Robinson, J. G. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.139 · Cited by 112
Ataluren: First Global Approval
Ryan, N. J. (2014) · Drugs · doi:10.1007/s40265-014-0287-4 · Cited by 112
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Machin, N., & Ragni, M. V. (2018) · Journal of Blood Medicine · doi:10.2147/jbm.s159297 · Cited by 111
A Small Molecule That Represses Translation of G-Quadruplex-Containing mRNA
Katsuda, Y., Sato, S., Asano, L., Morimura, Y., Furuta, T., Sugiyama, H., Hagihara, M., & Uesugi, M. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b04506 · Cited by 108
Craig, V. J., Tzankov, A., Flori, M., Schmid, C. A., Bader, A. G., & Mueller, A. (2012) · Leukemia · doi:10.1038/leu.2012.110 · Cited by 107
Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry
Rizvi, N. F., Howe, J. A., Nahvi, A., Klein, D. J., Fischmann, T. O., Kim, H., McCoy, M. A., Walker, S. S., Hruza, A. W., Richards, M. P., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b01013 · Cited by 107
Miniarikova, J., Zimmer, V., Martier, R., Brouwers, C. C., Pythoud, C., Richetin, K., Rey, M. J., Lubelski, J., Evers, M. M., van Deventer, S. J. H., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.71 · Cited by 106
Disney, M. D., Liu, B., Yang, W., Sellier, C., Tran, T. A., Charlet‐Berguerand, N., & Childs‐Disney, J. L. (2012) · ACS Chemical Biology · doi:10.1021/cb300135h · Cited by 105
Structure–function insights reveal the human ribosome as a cancer target for antibiotics
Myasnikov, A. G., Natchiar, S. K., Nebout, M., Hazemann, I., Imbert, V., Khatter, H., Peyron, J., & Klaholz, B. P. (2016) · Nature Communications · doi:10.1038/ncomms12856 · Cited by 105
Current Progress on aptamer-targeted Oligonucleotide Therapeutics
Dassie, J. P., & Giangrande, P. H. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.118 · Cited by 103
Leal, L., Guardo, A. C., Morón‐López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H., Gruters, R. A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002026 · Cited by 102
Steurer, M., Montillo, M., Scarfò, L., Mauro, F. R., Andel, J., Wildner, S. M., Trentin, L., Janssens, A. M., Burgstaller, S., Frömming, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205930 · Cited by 101
Lynch, S. R., Gonzalez, R. L., & Puglisi, J. D. (2003) · Structure · doi:10.1016/s0969-2126(02)00934-6 · Cited by 98
Application of aptamers for in vivo molecular imaging and theranostics
Bouvier‐Müller, A., & Ducongè, F. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.004 · Cited by 98
Gandhi, R. T., Kwon, D. S., Macklin, E. A., Shopis, J., McLean, A. P., McBrine, N., Flynn, T., Peter, L. E., Sbrolla, A., Kaufmann, D., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000852 · Cited by 97
Guide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems
Filippova, J. A., Matveeva, A. M., Zhuravlev, E. S., & Stepanov, G. A. (2019) · Biochimie · doi:10.1016/j.biochi.2019.09.003 · Cited by 97
Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95 · cited 1×
“They include the use of mRNAs encoding zinc finger nucleases (Geurts et al., 2009; Wood et al., 2011; Huang et al., 2014; Wang et al., 2015a; Conway et al., 2019), transcription activator–like effector nucleases (Tan et al.”
BackgroundBidirectional Transcription and the Regulation of Phage λ Repressor Synthesis
Spiegelman, W. G., Reichardt, L. F., Yaniv, M., Heinemann, S. F., Kaiser, A. D., & Eisen, H. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.11.3156 · Cited by 95
MicroRNAs as biomarkers for clinical studies
Pogribny, I. P. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217731291 · Cited by 95
Khan, N., Eliopoulos, H., Han, L., Kinane, T. B., Lowes, L. P., Mendell, J. R., Gordish‐Dressman, H., Henricson, E., McDonald, C. M., & on behalf of the Eteplirsen Investigators and the CINRG DNHS Investigators (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180351 · Cited by 95
Structural features of an influenza virus promoter and their implications for viral RNA synthesis
Bae, S.-H., Cheong, H., Lee, J., Cheong, C., Kainosho, M., & Choi, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191268798 · Cited by 94
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 94
mRNA: A Novel Avenue to Antibody Therapy?
Schlake, T., Thran, M., Fiedler, K., Heidenreich, R., Petsch, B., & Fotin‐Mleczek, M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.002 · Cited by 93
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
Warner, K. D., Homan, P., Weeks, K. M., Smith, A. G., Abell, C., & Ferré-D’Amaré, A. R. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.03.007 · Cited by 92
Wang, H., Mann, P. A., Xiao, L., Gill, C., Galgoci, A. M., Howe, J. A., Villafania, A., Barbieri, C. M., Malinverni, J. C., Sher, X., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.03.014 · Cited by 91
Structural Basis for Molecular Discrimination by a 3′,3′-cGAMP Sensing Riboswitch
Ren, A., Wang, X. C., Kellenberger, C. A., Rajashankar, K. R., Jones, R. A., Hammond, M. C., & Patel, D. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.004 · Cited by 89
How drug-like are ‘ugly’ drugs: do drug-likeness metrics predict ADME behaviour in humans?
Ritchie, T. J., & Macdonald, S. J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.007 · Cited by 88
MicroRNAs as Clinical Biomarkers and Therapeutic Tools in Perioperative Medicine
Kreth, S., Hübner, M., & Hinske, L. C. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002444 · Cited by 88
Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs
Velagapudi, S. P., Costales, M. G., Vummidi, B. R., Nakai, Y., Angelbello, A. J., Tran, T. A., Haniff, H. S., Matsumoto, Y., Wang, Z. F., Chatterjee, A. K., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.015 · Cited by 88
A New Era for Rare Genetic Diseases: Messenger RNA Therapy
Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 88
Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia
An, D., Frassetto, A., Jacquinet, E., Eybye, M., Milano, J., DeAntonis, C., Nguyen, V., Laureano, R., Milton, J., Sabnis, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.003 · Cited by 87
Su, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki731 · Cited by 87
Chauvier, A., Picard‐Jean, F., Berger-Dancause, J.-C., Bastet, L., Naghdi, M. R., Dubé, A., Turcotte, P., Perreault, J., & Lafontaine, D. A. (2017) · Nature Communications · doi:10.1038/ncomms13892 · Cited by 87
Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells
McMahon, M. A., Prakash, T. P., Cleveland, D. W., Bennett, C. F., & Rahdar, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.031 · Cited by 87
siRNA Design Software for a Target Gene-Specific RNA Interference
Naito, Y., & Ui‐Tei, K. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00102 · Cited by 86
Boyce, M. J., Warrington, S., Cortezi, B., Zöllner, S. K., Vauléon, S., Swinkels, D. W., Summo, L., Schwoebel, F., & Riecke, K. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13433 · Cited by 83
Anti-frameshifting Ligand Reduces the Conformational Plasticity of the SARS Virus Pseudoknot
Ritchie, D. B., Soong, J., Sikkema, W. K. A., & Woodside, M. T. (2014) · Journal of the American Chemical Society · doi:10.1021/ja410344b · Cited by 83
Caron, N. S., Southwell, A. L., Brouwers, C. C., Cengio, L. D., Xie, Y., Black, H. F., Anderson, L. M., Ko, S., Zhu, X., van Deventer, S. J. H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz976 · Cited by 83
Petrek, H. E., & Yu, A. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.528 · Cited by 82
Self-citationPan, Y.-Z., Zhou, A., Hu, Z., & Yu, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052092 · Cited by 81
Self-citationGermline transgenesis in rabbits by pronuclear microinjection of Sleeping Beauty transposons
Ivics, Z., Hiripi, L., Hoffmann, O. I., Mátés, L., Yau, T. Y., Bashir, S., Zídek, V., Landa, V., Geurts, A. M., Pravenec, M., et al. (2014) · Nature Protocols · doi:10.1038/nprot.2014.009 · Cited by 81
Chen, Q., Wang, W.-P., Zeng, S., Urayama, S., & Yu, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv228 · Cited by 81
Self-citationNallagatla, S. R., Toroney, R., & Bevilacqua, P. C. (2008) · RNA Biology · doi:10.4161/rna.5.3.6839 · Cited by 80
Ludwig, H., Weisel, K. C., Petrucci, M. T., Leleu, X. P., Cafro, A. M., Garderet, L., Leitgeb, C., Foà, R., Greil, R., Yakoub‐Agha, I., et al. (2017) · Leukemia · doi:10.1038/leu.2017.5 · Cited by 80
Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia
Xu, S., Luk, K., Yao, Q., Shen, A. H., Zeng, J., Wu, Y., Luo, H., Brendel, C., Pinello, L., Chui, D. H. K., et al. (2019) · Blood · doi:10.1182/blood-2019-01-895094 · Cited by 80
Howe, J. A., Xiao, L., Fischmann, T. O., Wang, H., Tang, H., Villafania, A., Zhang, R., Barbieri, C. M., & Roemer, T. (2016) · RNA Biology · doi:10.1080/15476286.2016.1216304 · Cited by 76
Ewe, A., Schaper, A., Barnert, S., Schubert, R., Temme, A., Bakowsky, U., & Aigner, A. M. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.02.037 · Cited by 75
Li, Y., & Disney, M. D. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00827 · Cited by 75
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents
Giorgio, A. D., & Duca, M. (2019) · MedChemComm · doi:10.1039/c9md00195f · Cited by 75
Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo
Ewe, A., Panchal, O., Pinnapireddy, S. R., Bakowsky, U., Przybylski, S., Temme, A., & Aigner, A. M. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.005 · Cited by 74
Keskin, S., Brouwers, C. C., Sogorb-González, M., Martier, R., Depla, J. A., Vallès, A., van Deventer, S. J. H., Konstantinova, P. S., & Evers, M. M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.010 · Cited by 73
de Paula Brandão, P. R., Titze-de-Almeida, S. S., & Titze-de-Almeida, R. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00438-6 · Cited by 72
Yi, W., Tu, M., Liu, Z., Zhang, C., Batra, N., Yu, A.-X., & Yu, A. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.001 · Cited by 72
Self-citationLi, X., Tian, Y. E., Tu, M., Ho, P. Y., Batra, N., & Yu, A. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.12.002 · Cited by 71
Self-citationSelection of hyperfunctional siRNAs with improved potency and specificity
Wang, X., Wang, X., Varma, R. K., Beauchamp, L., Magdaleno, S. M., & Sendera, T. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp864 · Cited by 70
Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates
Kelnar, K., Peltier, H. J., Leatherbury, N., Stoudemire, J., & Bader, A. G. (2014) · Analytical Chemistry · doi:10.1021/ac403044t · Cited by 70
Costales, M. G., Hoch, D. G., Abegg, D., Childs‐Disney, J. L., Velagapudi, S. P., Adibekian, A., & Disney, M. D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10558 · Cited by 70
Inhibition of Non-ATG Translational Events in Cells via Covalent Small Molecules Targeting RNA
Yang, W., Wilson, H. D., Velagapudi, S. P., & Disney, M. D. (2015) · Journal of the American Chemical Society · doi:10.1021/ja507448y · Cited by 69
Cited by
Molecular photoswitches in aqueous environments
Volarić, J., Szymanski, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 438
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Self-citationMicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
An ontology-based knowledge graph for representing interactions involving RNA molecules
Cavalleri, E., Cabri, A., Soto-Gomez, M., Bonfitto, S., Perlasca, P., Gliozzo, J., Callahan, T. J., Reese, J., Robinson, P. N., Casiraghi, E., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03673-7 · Cited by 33
Metadata
- Authors
- Yu, A.-M., Choi, Y. H., & Tu, M.-J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 72
- Issue
- 4
- Pages
- 862-898
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3084513853
- Cited by
- 395
- References
- 467
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.